Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 98Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Resectable Pancreatic Cancer 1

Interventions

Surveys and Questionnaires 529Blood Specimen Collection 406Surgical Procedures, Operative 152Radiotherapy 131Interviews as Topic 131Drug Therapy 123Observation 122Magnetic Resonance Spectroscopy 104Biopsy 103Specimen Handling 70Data Collection 70Neoadjuvant Therapy 65Immunohistochemistry 64Magnetic Resonance Imaging 61Immune Checkpoint Inhibitors 59Watchful Waiting 52Immunotherapy 51Bevacizumab 50Positron Emission Tomography Computed Tomography 46Ultrasonography 44Hematologic Tests 42Liquid Biopsy 41Tomography, X-Ray Computed 40Therapeutics 40Radiosurgery 40Colonoscopy 40pembrolizumab 37Hepatectomy 37Gene Expression Profiling 36High-Energy Shock Waves 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Observational × nimotuzumab × Clear all
NCT06363084 2024-04-12

A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Ruijin Hospital

Completed
64 enrolled
Gastrointestinal

Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡